Home:
Web Guide 1: Editor
Welcome to Colorectal Cancer Update
In recent years, treatment options for both primary and metastatic
colorectal cancer have improved with the availability of a number
of new, effective chemotherapeutic agents and combinations. The
future looks even brighter, as many more novel therapies and regimens
fill the pipeline.
This new series will provide practicing oncologists access to
the latest developments in clinical research. Utilizing an educational
model developed over the last 14 years in breast cancer, Colorectal
Cancer Update focuses on in-depth interviews with investigators
specializing in colorectal cancer clinical research. The perspectives,
opinions and experiences of these research leaders allow busy, practicing
oncologists to take away practical strategies that can be utilized
in daily patient care.
As in our breast cancer series, this audio program is supplemented
by a website ColorectalCancerUpdate.com which contains
full transcripts from the interviews and related links to journal
articles, abstracts and protocols. Colorectal cancer is a disease
with many more therapeutic options than even five years ago. Our
goal is to provide valuable research information and viewpoints
that can be applied to clinical decision-making for the thousands
of men and women with this disease. We look forward to many more
issues.
Neil Love, MD
Editor
Select Agents in Phase II/III Colorectal Clinical
Trials in the NCIs PDQ data base |
Avastin®
|
(bevacizumab) |
BiCNU®
|
(carmustine) |
BMS-247550 |
(investigational epothilone B analog) |
Camptosar® |
(irinotecan, CPT-11) |
Eloxatine® |
(oxaliplatin) |
Erbitux® |
(cetuximab, IMC-C225) |
Ergamisol® |
(levamisole) |
Herceptin® |
(trastuzumab) |
Iressa® |
(ZD 1839) |
Panorex® |
(edrecolomab) |
Rubivive® |
(rubitecan, RFS 2000) |
Taxol® |
(paclitaxel) |
Thalomid® |
(thalidomide) |
Xeloda® |
(capecitabine) |
|